The information set forth in Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following information thereto: On September 23, 2025, Gold Fields Limited through two of its wholly-owned subsidiaries: (i) Marsh Holdings Inc. ("Marsh") and (ii) Gold Fields Orogen Holding (BVI) Limited ("GF Orogen", and together with Marsh, the "Selling Shareholders") sold an aggregate of 50,471,657 common shares of the Issuer at a price of C$3.00 per Common Share, for total gross proceeds to the Selling Shareholders of approximately C$151,414,971 (the "Sale"). The Sale was made as a bought deal block trade to BMO Capital Markets, Scotiabank and CIBC Capital Markets, as principals. Immediately prior to the Sale, the Reporting Persons beneficially owned an aggregate of 50,471,657 common shares (of which 21,971,657 common shares were held by Marsh and 28,500,000 common shares were held by GF Orogen), representing approximately 19.5% of the issued and outstanding common shares. Following completion of the Sale, the Reporting Persons no longer own or control any common shares. However, pursuant to a share purchase agreement dated as of December 20, 2023 between GF Orogen, Galiano and certain of their affiliates (the "Share Purchase Agreement") under which Galiano acquired all of Gold Fields' 50% joint venture interest in the Asanko gold mine in Ghana, Galiano and its subsidiaries may elect to pay certain of the deferred acquisition consideration to GF Orogen in the form of Galiano common shares instead of cash. Specifically, the Share Purchase Agreement provides that in respect of certain required cash payments of US$25,000,000 due on or before December 31, 2025 (the "First Deferred Consideration") and US$30,000,000 due on or before December 31, 2026 (the "Second Deferred Consideration"), Galiano may elect to satisfy up to 20% of each of these amounts through the issuance of common shares, provided that such issuance of common shares does not result in the Gold Fields group holding more than 19.9% of the issued and outstanding common shares of the Issuer. If Galiano makes such election, such common shares will be issued at a deemed issue price equal to the volume-weighted average trading price ("VWAP") of the common shares of the Issuer on the NYSE American stock exchange (the "NYSE") for the five (5) trading days immediately preceding the date of such issuance. For illustrative purposes, if Galiano were to elect to satisfy the maximum of 20% of both the First Deferred Consideration and the Second Deferred Consideration in common shares, and assuming a deemed issue price of US$2.47 (being the VWAP of the common shares of the Issuer on the NYSE for the five (5) trading days immediately precedeing September 15, 2025), then the number of Galiano Shares issuable to GF Orogen would be 4,453,441 shares, representing approximately 1.7% of the total issued and outstanding common shares of the Issuer.

Items 5(a) -(e) of the Schedule 13D are hereby amended and restated as follows: As of the date of this filing the Reporting Persons may be deemed the beneficial owners of 0 securities of the Issuer, representing 0% of the Issuer's issued and outstanding common shares.

As of the date of this filing the Reporting Persons may be deemed to have the shared power to vote and dispose of 0 common shares.

To the best of the Reporting Persons' knowledge, there were no transactions in the common shares effected by the Reporting Persons during the past 60 days and not previously reported.

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any of the common shares beneficially owned by the Reporting Persons.

As of September 23, 2025, the Reporting Persons ceased to be the beneficial owner of more than 5% of the securities of the Issuer. The filing of this Amendment No. 4 represents the final amendment to the Schedule 13D and constitutes an exit for the Reporting Persons.